Efavirenz-induced psychosis [3]

AIDS

Volumn 15, Issue 14, 2001, Pages 1911-1912

  De La Garza, César Luis Sanz ^a   Paoletti Duarte, Santos ^b   García Martín, Carlos ^b   Gutiérrez Casares, Jose Ramón ^c  

^a Centro de Salud Mental de Cangas de Narcea   (Spain)

^b Hospital Nuestra Senora de la Montana   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; HALOPERIDOL; LAMIVUDINE; LORATADINE; LORAZEPAM; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIBIOTIC THERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SKIN DISEASE;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; OXAZINES; PSYCHOSES, SUBSTANCE-INDUCED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035964661     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109280-00033     Document Type: Letter

References (4)

1. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society USA panel
2. L-743, 726 (DMP-266): A novel highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
3. Pharmacokinetic and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
4. A phase II multicenter randomised, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV)+indinavir (IDV), versus EFV+zidovudine (ZDV)+lamivudine (3TC), versus IDV+TC at >36 weeks